key: cord-0767085-dqg6ecxj authors: Sapkal, Gajanan N.; Yadav, Pragya D.; Ella, Raches; Deshpande, Gururaj R.; Sahay, Rima R.; Gupta, Nivedita; Mohan, V Krishna; Abraham, Priya; Panda, Samiran; Bhargava, Balram title: Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum date: 2021-01-27 journal: bioRxiv DOI: 10.1101/2021.01.26.426986 sha: ebddd97d9c897f18b30deed2bd0f5d92956f4b5a doc_id: 767085 cord_uid: dqg6ecxj We performed the plaque reduction neutralization test (PRNT50) using sera collected from the recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape. We performed the plaque reduction neutralization test (PRNT 50 ) using sera collected from the recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape. The rapid surge in SARS-CoV-2 cases due to the Variant of Concern (VOC) 202012/01, also known as lineage B.1.1.7 or 20B/501Y.V1, in the United Kingdom (UK) 1 raised concerns in several countries. Many of these countries had direct flights to and from UK and the variant was associated with high transmissibility. Identification of other variants from South Africa 2 also initiated a global discussion on the challenges that these new variants could pose to the current vaccine candidates. The genome of the UK-variant has seventeen mutations, eight of which were found in spike receptor-binding domain (RBD) mediating the attachment of the virus to the angiotensin converting enzyme 2 (ACE2) receptor on the surface of human cells. 2 Therefore, it appeared that the majority of the vaccine candidates, being either recombinant or specifically targeting the single epitope of original D614G ancestral spike sequence, might not be able to generate an efficient immune response against the new variants. Here, we successfully isolated and characterized the hCoV-19/India/20203522 SARS-CoV-2 (VOC) 202012/01 from UKreturnees in India with all signature mutations of the UK-variant. 3 Earlier, we have reported development of an inactivated whole-virion SARS-CoV-2 vaccine BBV152 (COVAXIN™), which elicited remarkable neutralizing antibody response in phase I clinical trial against hCoV-19/India/2020770 (homologous), and two heterologous strains from the unclassified cluster namely hCoV-19/India/2020Q111 and hCoV-19/India/2020Q100. 4 In phase II clinical trial, the vaccine candidate showed noteworthy results with plaque reduction neutralization test (PRNT 50 ). The sero-conversion rate with neutralizing antibodies (NAb) following vaccination with BBV152 was 99.6%. 5 Here, we present the NAb titers (PRNT 50 ) of sera collected from vaccine recipients, who had received BBV152 vaccine-candidate in phase-II trial 4 to underline the efficacy of BBV152 vaccine candidate against SARS-CoV-2 UK-variant (tested with sera of 38 human subjects) and one of the heterologous strains hCoV-19/India/2020Q111 (unclassified cluster) (tested with sera of 20 human subjects) using plaque reduction neutralization test as described earlier 6 . All the sera had equivalent NAb titers to hCoV-19/India/2020770 homologous strain and two heterologous strains with the characteristic N501Y substitution of the UK-variant; hCoV-19/India/20203522 (UK strain) as well as hCoV-19/India/2020Q111 (Figure 1 A and B) . The median ratio of 50% neutralization of sera was found to be 0.8 when compared with hCoV- Andreano E et al. reported an escape of the UK-variant with E484K substitution, which was followed by an 11-amino-acid insertion in the NTD N5 loop (248aKTRNKSTSRRE248k) from high NAb in convalescent plasma, which was a serious concern pertaining to the potential efficacy of the vaccines. 7 Our study evidently highlighted comparable neutralization activity of vaccinated individuals sera against variant as well as heterologous SARS-CoV-2 strains. Importantly, sera from the vaccine recipients could neutralise the UK-variant strains discounting the uncertainty around potential escape. It was reassuring from the PRNT 50 data generated in our 4 laboratory that the indigenous BBV152/ COVAXIN™, following its roll out in vaccination program, could be expected to work against the new UK-variant. It is unlikely that the mutation 501Y would be able to dampen the potential benefits of the vaccine in concern. New variant of SARS-CoV-2 in UK causes surge of COVID-19 Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding In a 1st, NIV-Pune isolates, cultures Covid's UK variant A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma PRNT 50 ) of vaccine's sera against hCoV-19/India/2020770 (homologous), hCoV-19/India/20203522 (heterologous UK strain) and hCoV-19/India/2020Q111 (heterologous unclassified cluster). The bar represents the geometric mean and standard deviation of the respective group titers. Non-parametric Kruskal-Wallis test was used for the comparison of the PRNT 50 values from different groups •05 were considered non-significant and are marked on the figure (ns-non-significant). (B) Comparison of PRNT 50 value of each vaccine recipient's sera with three strains of SARS CoV-2: Neutralizing antibody titers (PRNT 50 ) of each vaccinees' sera against hCoV /India/2020770 (homologous), hCoV-19/India/20203522 (heterologous UK strain) and hCoV The bar represents the mean and standard deviation of the respective sera We thank the scientific staff of Maximum Containment Facility, ICMR-NIV, Pune Dr. Dimpal The data that support the findings of this study are available from the corresponding authors upon reasonable request. PDY and GNS contributed to study design, data collection, data analysis, interpretation, writing and critical review. GRD and RE contributed to data analysis and interpretation, writing and critical review. RRS, NG, VKM and SP contributed to data collection, writing and critical review. PA and BB contributed to writing and critical review of the manuscript. The authors declared no competing interest 5 Financial support was provided by the Department of Health Research, Ministry of Health and Family Welfare, New Delhi, at ICMR-National Institute of Virology, Pune.